Soft Tissue and Bone Sarcomas in Association with Pregnancy

Management of a parturient with high-grade osteosarcoma of the proximal femur: a multidisciplinary approach

“…The occurrence of osteosarcoma in pregnant women is uncommon and the influence of pregnancy on the proliferation of these tumors remains unclear. 1 It has been postulated that the hormonal changes which occur during pregnancy can contribute to the growth and recurrence of sarcomas in susceptible individuals; however, there is no clear evidence that pregnancy adversely affects the course of the disease. 7 Although sarcomas rarely develop during pregnancy, musculoskeletal pain, especially involving the lower back and pelvic structures, is a common occurrence.…”

“…1 Three decades ago, amputation was the sole treatment for osteosarcoma and the five-year survival rate was less than 20% due to distant metastatic disease. [2][3][4] With the introduction of early resection and adjuvant chemotherapy, 60-80% of patients with localized disease can be treated with limb salvage surgery and are long-term survivors.…”

Sarcoma of the Ewing Family in Pregnancy: A Case Report of Intrauterine Fetal Death after Induction of Chemotherapy

“…Surgical procedures, such as open biopsy, tumor resection, and limb-sparing surgery, are regarded as relatively safe during gestation [4]. The risk of chemotherapy during pregnancy depends on the drugs used and the gestational age of the fetus.…”

“…Breast cancer is the most common tumor treated during gestation followed by ovarian cancer, cervical cancer, leukemia, lymphoma, and lung cancer [1, 2]. Bone and soft tissue sarcomas, being generally rare diseases, present more infrequently during gestation [3, 4]. In total, 12 patients with sarcoma [5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16] and 1 with a primitive neuroectodermal tumor [17] have been treated with chemotherapy while being pregnant.…”

Primary Pulmonary Synovial Sarcoma during Pregnancy: A Diagnostic and Therapeutic Dilemma

“…Neoadjuvant chemotherapy would necessarily focus on containing the growth of the mass, with hopes of inducing tumor necrosis, without causing undue harm to the fetus. A literature review yielded data supporting clinical benefit and acceptable third-trimester fetal risk associated with ifosfamide [7, 8, 9]. She was given 2 cycles of ifosfamide as follows: 2 g/m 2 IV bolus over 4 h followed by 2 g/m 2 /day as continuous IV infusions for 6 days (the total dose given was 14 g/m 2 /cycle) each along with mesna.…”